Cargando…
Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells
We recently demonstrated that the histone deacetylase inhibitor valproic acid (VPA) reprograms the cisplatin-induced metabolome of triple-negative breast cancer (TNBC) cells, including a shift in hexose levels. Accordingly, here, we tested the hypothesis that VPA alters glucose metabolism in correla...
Autores principales: | Granit Mizrahi, Avital, Gugenheim, Ahinoam, Hamad, Haneen, Hamed, Roa’a, Tetro, Nino, Maimon, Ofra, Khutsurauli, Salome, Nechushtan, Hovav, Nisman, Benjamin, Duran, Deborah, Samman, Widad, Birimberg-Schwartz, Liron, Grunewald, Myriam, Eyal, Sara, Peretz, Tamar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639136/ https://www.ncbi.nlm.nih.gov/pubmed/37954205 http://dx.doi.org/10.3389/fcell.2023.1217149 |
Ejemplares similares
-
Lacosamide at therapeutic concentrations induces histone hyperacetylation in vitro
por: Granit, Avital, et al.
Publicado: (2018) -
Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin
por: Granit, Avital, et al.
Publicado: (2022) -
Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer
por: Bentata, Mercedes, et al.
Publicado: (2020) -
New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
por: Nisman, Benjamin, et al.
Publicado: (2016) -
Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2019)